JP2021520788A5 - - Google Patents

Info

Publication number
JP2021520788A5
JP2021520788A5 JP2020555033A JP2020555033A JP2021520788A5 JP 2021520788 A5 JP2021520788 A5 JP 2021520788A5 JP 2020555033 A JP2020555033 A JP 2020555033A JP 2020555033 A JP2020555033 A JP 2020555033A JP 2021520788 A5 JP2021520788 A5 JP 2021520788A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
sequence
cell
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020555033A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021520788A (ja
JP7479290B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/026840 external-priority patent/WO2019200007A1/en
Publication of JP2021520788A publication Critical patent/JP2021520788A/ja
Publication of JP2021520788A5 publication Critical patent/JP2021520788A5/ja
Application granted granted Critical
Publication of JP7479290B2 publication Critical patent/JP7479290B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020555033A 2018-04-10 2019-04-10 Dll3に対するキメラ受容体及びその使用方法 Active JP7479290B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862655725P 2018-04-10 2018-04-10
US62/655,725 2018-04-10
PCT/US2019/026840 WO2019200007A1 (en) 2018-04-10 2019-04-10 Chimeric receptors to dll3 and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2021520788A JP2021520788A (ja) 2021-08-26
JP2021520788A5 true JP2021520788A5 (cg-RX-API-DMAC7.html) 2022-04-18
JP7479290B2 JP7479290B2 (ja) 2024-05-08

Family

ID=66248863

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020555033A Active JP7479290B2 (ja) 2018-04-10 2019-04-10 Dll3に対するキメラ受容体及びその使用方法

Country Status (27)

Country Link
US (1) US12012462B2 (cg-RX-API-DMAC7.html)
EP (1) EP3773912A1 (cg-RX-API-DMAC7.html)
JP (1) JP7479290B2 (cg-RX-API-DMAC7.html)
KR (1) KR102951376B1 (cg-RX-API-DMAC7.html)
CN (1) CN112334193A (cg-RX-API-DMAC7.html)
AR (1) AR114283A1 (cg-RX-API-DMAC7.html)
AU (2) AU2019251473A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020020857A2 (cg-RX-API-DMAC7.html)
CA (1) CA3095920A1 (cg-RX-API-DMAC7.html)
CL (3) CL2020002613A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020013392A2 (cg-RX-API-DMAC7.html)
CR (1) CR20200539A (cg-RX-API-DMAC7.html)
EA (1) EA202092417A1 (cg-RX-API-DMAC7.html)
IL (1) IL277735B1 (cg-RX-API-DMAC7.html)
JO (1) JOP20200259A1 (cg-RX-API-DMAC7.html)
MA (1) MA52203A (cg-RX-API-DMAC7.html)
MX (1) MX2020010753A (cg-RX-API-DMAC7.html)
MY (1) MY203383A (cg-RX-API-DMAC7.html)
PE (1) PE20211396A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551671A1 (cg-RX-API-DMAC7.html)
SA (1) SA520420301B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202009923TA (cg-RX-API-DMAC7.html)
TW (1) TWI842703B (cg-RX-API-DMAC7.html)
UA (1) UA129466C2 (cg-RX-API-DMAC7.html)
UY (2) UY41150A (cg-RX-API-DMAC7.html)
WO (1) WO2019200007A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202006943B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118126157A (zh) 2017-08-03 2024-06-04 美国安进公司 白介素-21突变蛋白和治疗方法
MX2020007291A (es) 2018-01-12 2020-09-10 Amgen Inc Anticuerpos anti-pd-1 y metodos de tratamiento.
EP4527466A3 (en) 2019-07-17 2025-06-18 Legend Biotech Ireland Limited Anti-dll3 chimeric antigen receptors and uses thereof
US20230272035A1 (en) * 2019-12-05 2023-08-31 Vycellix, Inc. Modulators of the immune escape mechanism for universal cell therapy
TW202200615A (zh) 2020-03-12 2022-01-01 美商安進公司 用於治療和預防患者的crs之方法
WO2021180215A1 (en) 2020-03-12 2021-09-16 Nanjing Legend Biotech Co., Ltd. Glypican-2-binding moieties, chimeric antigen receptors and uses thereof
US20240150456A1 (en) * 2021-04-02 2024-05-09 Nanjing Legend Biotech Co., Ltd. Engineered immune cells and uses thereof
US20240239878A1 (en) * 2021-05-08 2024-07-18 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Binding molecule against dll3 and use thereof
WO2022240688A1 (en) * 2021-05-10 2022-11-17 Amgen Inc. Dosing regimen for combination therapy targeting dll3 and pd-1
EP4370541A1 (en) 2021-07-14 2024-05-22 2seventy bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
CA3230627A1 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Antigen recognizing receptors targeting dll3 and uses thereof
CA3245384A1 (en) 2022-03-03 2023-09-07 Cambridge Enterprise Limited Therapeutic antibodies
AU2023248532A1 (en) 2022-04-08 2024-11-21 Regeneron Pharmaceuticals, Inc. Multipartite receptor and signaling complexes
WO2023199069A1 (en) 2022-04-14 2023-10-19 Crescendo Biologics Limited Chimeric antigen receptor that binds mesothelin
WO2024026284A2 (en) * 2022-07-25 2024-02-01 Interius Biotherapeutics, Inc. Mutated polypeptides, compositions comprising the same, and uses thereof
CN116003628B (zh) * 2022-08-15 2026-08-04 南京博安生物技术有限公司 靶向人dll3抗原的全人源特异性嵌合抗原受体及其应用
CN116813784B (zh) * 2023-05-17 2024-03-01 星奕昂(上海)生物科技有限公司 靶向dll3的抗体及其应用
KR20260079181A (ko) * 2023-09-26 2026-06-01 레전드 바이오테크 유에스에이, 인크. Dll3 결합 모이어티 및 이의 용도
CN122094981A (zh) * 2023-10-16 2026-05-26 上海先博生物科技有限公司 一种靶向δ样配体3的CAR及应用
GB202402046D0 (en) 2024-02-14 2024-03-27 Bivictrix Ltd Therapeutic antibodies
GB202402048D0 (en) 2024-02-14 2024-03-27 Bivictrix Ltd Therapeutic antibodies
WO2025202653A1 (en) 2024-03-27 2025-10-02 Ucl Business Ltd T-cell therapy targetting mutant calreticulin
WO2026039940A1 (zh) * 2024-08-19 2026-02-26 南京博安生物技术有限公司 一种增强型靶向dll3蛋白的嵌合抗原受体和突变体以及应用
GB202412771D0 (en) 2024-08-30 2024-10-16 Cambridge Entpr Ltd Therapeutic molecules
CN119241712B (zh) * 2024-12-05 2025-05-06 晟临生物医药(上海)有限公司 抗dll3的纳米抗体、嵌合抗原受体及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5830462A (en) 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US20030036654A1 (en) 1994-08-18 2003-02-20 Holt Dennis A. Synthetic multimerizing agents
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7229960B2 (en) * 2000-11-03 2007-06-12 University Of Vermont And State Agricultural College Methods and compositions for inhibiting GRB7
US20100196336A1 (en) 2006-05-23 2010-08-05 Dongsu Park Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9024028B2 (en) 2011-01-26 2015-05-05 Ariad Pharmaceuticals, Inc. Methods and compositions for the synthesis of multimerizing agents
WO2012129514A1 (en) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
JP6267644B2 (ja) * 2011-10-20 2018-01-24 アメリカ合衆国 抗cd22キメラ抗原受容体
CN104520324A (zh) * 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法
IL305629A (en) 2013-02-15 2023-11-01 Univ California Chimeric antigen receptor and methods of using it
CA2905352A1 (en) 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
EP3027204B1 (en) 2013-07-29 2022-01-05 2seventy bio, Inc. Multipartite signaling proteins and uses thereof
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
KR20240164967A (ko) 2014-02-04 2024-11-21 카이트 파마 인코포레이티드 B 세포 악성종양 및 다른 암을 치료하는데 유용한 자가 t 세포 및 그의 조성물의 생산 방법
EP3104866A4 (en) 2014-02-14 2017-08-02 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
MA41613A (fr) * 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
TWI793062B (zh) * 2015-07-31 2023-02-21 德商安美基研究(慕尼黑)公司 Dll3及cd3抗體構築體
AU2017240801A1 (en) * 2016-04-01 2018-10-25 Amgen Inc. Chimeric receptors to FLT3 and methods of use thereof
CN107400168B (zh) * 2017-07-18 2020-02-07 深圳市免疫基因治疗研究院 一种基于cd117的嵌合抗原受体及其应用

Similar Documents

Publication Publication Date Title
JP2019516352A5 (cg-RX-API-DMAC7.html)
JP2022523781A5 (cg-RX-API-DMAC7.html)
HRP20221348T1 (hr) Kimerni receptori i postupci njihove uporabe
JP2023516008A5 (cg-RX-API-DMAC7.html)
JP2021530233A5 (cg-RX-API-DMAC7.html)
JP2025032091A5 (cg-RX-API-DMAC7.html)
JP2019515661A5 (cg-RX-API-DMAC7.html)
JP2017524367A5 (cg-RX-API-DMAC7.html)
JP2021000103A5 (cg-RX-API-DMAC7.html)
JP2019516350A5 (cg-RX-API-DMAC7.html)
RU2017105160A (ru) Лечение рака с помощью химерного антигенного рецептора к cd33
CN112912401B (zh) 抗-l1细胞粘附分子抗体或其抗原结合片段及包含其的嵌合抗原受体
JP2024539506A5 (cg-RX-API-DMAC7.html)
JP2020513839A5 (cg-RX-API-DMAC7.html)
JP2021518142A5 (cg-RX-API-DMAC7.html)
JP2020513828A5 (cg-RX-API-DMAC7.html)
RU2017105161A (ru) Лечение рака с использованием химерного антигенного рецептора cll-1
RU2017105065A (ru) Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма
JP2018538339A5 (cg-RX-API-DMAC7.html)
JP2022538425A5 (cg-RX-API-DMAC7.html)
JP2017513818A5 (cg-RX-API-DMAC7.html)
JP2017530694A5 (cg-RX-API-DMAC7.html)
RU2020134294A (ru) Антитела против сигнал-регуляторного белка альфа и способы их применения
RU2019128921A (ru) Антитело к il-13ra2 и его применение
JP2023518930A5 (cg-RX-API-DMAC7.html)